10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group

Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually.